New FDA Warning Letters Highlight CGMP Deviations at API Plants in China, India
By Zachary Brennan -
Published 14 March 2017
The US Food and Drug Administration (FDA) on Tuesday released two new warning letters for active pharmaceutical ingredient manufacturers Badrivishal Chemicals & Pharmaceuticals and Lumis Global Pharmaceuticals, both sent 2 March.
Categories: News, Asia, FDA, Active pharmaceutical ingredients, Compliance, Drugs, Government affairs
Tags: warning letters, API manufacturers, water and pharmaceuticals